Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04077099 · ClinicalTrials.gov registry record · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
A Phase 1 study of NSCLC, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT04077099: Recruiting Phase 1 study of NSCLC, sponsored by Regeneron Pharmaceuticals.
NCT04077099 is a Phase 1 study of NSCLC that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 231 participants, roughly in line with the 221-participant average among 71 other NSCLC trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04077099, a Phase 1 study of NSCLC, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
Primary Outcome
Phase 1/Dose escalation
Conditions Studied
Interventions
- DRUG REGN5093
Study Locations (20)
New York
- NYU Cancer Institute - New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Massachusetts
- DNU_Massachusetts General Hospital_DNU - Boston
- Dana Farber Harvard Cancer Center Consortium - Boston
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh UPMC - Clinical Research Services - Pittsburgh
Texas
- Harold C. Simmons Comprehensive Cancer Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California Irvine Medical Center - Bldg 56, RT81, Rm 241 - Orange
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Moffitt Cancer Center - McKinley Drive - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2020-01-07 |
| Est. Completion | 2032-04-22 |
| Phase | Phase 1 |
What NCT04077099 shows while recruiting
NCT04077099 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 221-participant average among 71 other NSCLC trials with a reported enrollment target.
The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 1 intervention - of which REGN5093 is the first listed.
NCT04077099 names 20 study sites across 15 states, led by New York, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04077099 about?
NCT04077099 is a clinical study titled "A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer". This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of...
What is the current status of trial NCT04077099?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 2020-01-07. Estimated completion is 2032-04-22.
What conditions does trial NCT04077099 study?
This clinical trial studies the following conditions: NSCLC.
What interventions are being tested in trial NCT04077099?
The interventions under investigation include: REGN5093 (DRUG).
Who is sponsoring clinical trial NCT04077099?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04077099 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04077099's enrollment target sits among peer trials
231 24th of 71 higher than 48 of 71 other NSCLC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NSCLC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
- NCT06749457 · 231 participants · Phase 1
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI